The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases

Alexa DeMaio1, Shikhar Mehrotra2, Kumar Sambamurti3 and Shahid Husain1*

Abstract
The adaptive immune system and associated inflammation are vital in surveillance and host protection against internal and external threats, but can secondarily damage host tissues. The central nervous system is immune-privileged and largely protected from the circulating inflammatory pathways. However, T cell involvement and the disruption of the blood–brain barriers have been linked to several neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis. Under normal physiological conditions, regulatory T cells (Treg cells) dampen the inflammatory response of effector T cells. In the pathological states of many neurodegenerative disorders, the ability of Treg cells to mitigate inflammation is reduced, and a pro-inflammatory environment persists. This perspective review provides current knowledge on the roles of T cell subsets (e.g., effector T cells, Treg cells) in neurodegenerative and ocular diseases, including uveitis, diabetic retinopathy, age-related macular degeneration, and glaucoma. Many neurodegenerative and ocular diseases have been linked to immune dysregulation, but the cellular events and molecular mechanisms involved in such processes remain largely unknown. Moreover, the role of T cells in ocular pathologies remains poorly defined and limited literature is available in this area of research. Adoptive transfer of Treg cells appears to be a vital immunological approach to control ocular pathologies. Similarities in T cell dysfunction seen among non-ocular neurodegenerative diseases suggest that this area of research has a great potential to develop better therapeutic agents for ocular diseases and warrants further studies. Overall, this perspective review article provides significant information on the roles of T cells in numerous ocular and non-ocular neurodegenerative diseases.

Keywords: T cells, Neurodegeneration, Inflammation, Immune system, Lymphocytes

Adaptive immune responses and pathological conditions
The immune system can be divided into innate and adaptive immune responses and is designed to protect the body from disease-causing pathogens. The innate immune system is the body’s first line of defense and requires no lag time to mount a response to infection. Innate immunity is largely nonspecific. Adaptive immunity is much more specific and provides long-lasting protection against pathogens [5, 176]. The cells that carry out adaptive immune responses are called lymphocytes and are classified into B lymphocytes and T lymphocytes, which accomplish humoral and cell-mediated immune responses, respectively [279]. In the humoral immune response, a B cell receptor reacts with a specific antigen stimulating the cell to synthesize and secrete antibodies, also known as immunoglobulins. These antibodies play crucial roles in neutralizing pathogens [5, 289]. Antibodies recognize epitopes on a single specific molecule (e.g., protein or carbohydrate) called an antigen. When an antigen, such as a virus or microbial toxin
MHC class I, whereas CD4+ cells. When the CD8+ T cell has been primed by an APC, the T cell will expand its population to lymphoid tissues, such as lymph nodes [178]. After activation by an APC, the T cell will expand its population to eliminate the specific pathogen [152–154]. Once a population of T cells has been created to combat pathogens, memory T cells will provide lifelong immunity against the pathogen [91]. Mechanistically, CD8+ T cells bind to MHC class I, whereas CD4+ T cells bind to MHC class II [110]. Once a CD8+ T cell has been primed by an APC cell, it is activated and ready to kill infected or invading cells. When the CD8+ T cell binds to its target antigen on the surface of an infected cell, it will release lytic granules containing perforins and granzymes that create pores in the target cell membrane or it induces apoptosis via Fas ligand and caspase activation [362]. In addition, CD8+ T cells release cytokines including IFN-γ, TNF-α, and TNF-β. These cytokines will further inhibit viral replication, activate macrophages, and upregulate MHC class I expression. MHC class I expression increases the detection of an infected cell, as T cells cannot recognize cells without MHC molecules [121, 152–154].

CD4+ T cells were originally subdivided into two groups based on their effector functions: Th1 and Th2 cells. These Th1 and Th2 cells are antagonistic and maintain a balance under physiological conditions. Th1 cells, generally, secrete pro-inflammatory molecules such as IFN-γ, TNF-α, TNF-β, and IL-1β; while Th2 cells counteract inflammation with IL-4, IL-5, IL-6, IL-10, and IL-13 [25, 233, 361]. Until the mid-1990s, scientists were not aware of other subsets of CD4+ cells [63], but now CD4+ T cells have been expanded further into Th9, Th17, Th22, Treg cells, and T follicular cells [9, 110]. Th9, Th17, and Th22 T cell subsets secrete different pro-inflammatory cytokines and have been implicated in autoimmune and inflammatory diseases [193, 311, 328]. For example, in allergic asthma Th2, Th9, and Th17 cells play a role in the pathogenesis of the disease through cytokine secretion and the activation of mast cells and eosinophils, which leads to airway hyperactivity [174]. While the ability of T cells to cause inflammation may be necessary for proper immune function, a mechanism to regulate this response is also required. T regulatory (Treg) cells have been shown to play key roles in their regulation [14, 180, 244, 267, 342]. As evident from the name, Treg cells regulate and suppress the potentially dangerous effects of T cells and ultimately promote tolerance. Numerous functions of Treg cells have been documented including suppression of asthma and allergy [45, 51, 287], induction of tolerance to dietary antigens [12, 106], protection of commensal bacteria from elimination by the immune system [40], promotion of maternal–fetal tolerance [135], and prevention of autoimmune disease [63, 117, 333, 334]. The role of Treg cells is not fully understood, and it remains a key area of research, specifically in ocular pathology. However, it has become increasingly clear that Treg cells are required to maintain homeostasis. As referenced above, a hyperactive inflammatory immune response can harm host cells. Conversely, a lack of a properly functioning immune system can lead to life-threatening infections, so a balance must be struck between the two states. Treg cells maintain this balance by playing a suppressive role and preventing a pro-inflammatory response [189]. Numerous disease conditions such as systemic sclerosis [215], gestational diabetes [286], atherosclerosis [138], COPD [149], among many others have reported T cell subsets imbalance as a causative factor in disease pathogenesis.

**Tolerance and autoimmunity**

The immune system is designed to target foreign pathogens and leave host cells unharmed via a process known as tolerance. Autoimmunity occurs when a host loses self-tolerance. In other words, autoimmunity is a process of an immune response against the host leading to self-cell damage. Different autoimmune conditions can target specific areas of the body like pemphigus vulgaris and pemphigoid, which targets the skin [122], or systemic lupus erythematosus which is disseminated and targets the entire body [182]. An important aspect of autoimmunity is the presence of autoreactive lymphocytes. Auto-reactivity can be triggered through molecular mimicry, which is immunological cross-reactivity between host and foreign antigens. In this condition, foreign antigens closely resemble host antigens resulting in an erroneous self-directed attack on host tissue [67]. Autoreactive lymphocytes can also develop during the
initial lymphocyte creation. When lymphocytes undergo genetic rearrangement, some are reactive against self-antigens, but under homeostatic conditions these lymphocytes undergo thymic deletion and undergo apoptosis [331]. Although up to 98% of T cells do not make it through the selection process [24], some autoreactive lymphocytes will escape the process of elimination even in healthy individuals [266]. One of the functions of Treg cells is to prevent the activation of these autoreactive lymphocytes and therefore protect the body from self-attack [297]. FoxP3 knockdown, a marker for Treg cells, leads to a loss of functional Treg cells in Scurfy mice [231]. The lack of Treg cells leads to a fatal autoimmune response by 3–4 weeks of age, demonstrating their critical role in immune tolerance. T cells activation suppression via the induction of anergy, a long-term state of T cell hypo-responsiveness, is the second mechanism of its modulation [43]. Inducing anergy will prevent T cells from undergoing clonal proliferation, providing another potential fail-safe against autoimmunity. Recent studies have shown a strong connection between Treg cells and anergy, anergic T cells can convert into Treg cells, suggesting that persistent anergic T cells may serve as a reservoir for Treg cells, though the mechanism remains largely unknown [246, 292].

Autoimmune diseases affect millions of people with increasing frequency in developing countries, making them an important area of study [265]. Some autoimmune conditions are hereditary, and many primarily affect women, but they typically require a trigger or underlying susceptibility [62]. Autoimmunity is multifactorial and involves genetic, environmental, hormonal, immunological, and unknown triggers [302]. Modifiable risk factors for autoimmune diseases include infection [185], vaccination [329], drugs [72], smoking [268], UV light exposure [166] and obesity [302]. Studies have also shown that people with autoimmune diseases are less active than the rest of the population, suggesting physical activity may play a regulatory role in autoimmunity [284].

**Adaptive immunity and Alzheimer’s disease**

Alzheimer’s disease (AD) is a neurodegenerative disorder and one of the most common causes of senile dementia worldwide. The loss of memory and cognitive decline was seen in AD is progressive, irreversible, and is usually seen in the elderly population. Characteristic features of the disease are the accumulation of β-amyloid plaque deposits as well as neurofibrillary tangles of hyper-phosphorylated tau in the brain [30, 78, 82, 339]. However, the familial AD (FAD) mouse models combined with frontotemporal dementia-linked human microtubule associated tau fail to show the extensive and progressive neurodegeneration reported in human patients [230]. Therefore, there is a major gap in our understanding of the steps leading to neurodegeneration and irreversible dementia. The evidence for immune system involvement in AD is compelling. Several studies have implicated both microglia and the innate immune system in the neurodegeneration seen in AD [29, 280]. Studies have also shown the involvement of the adaptive immune system in the pathology of AD. T cells have been identified in the brain parenchyma of postmortem Alzheimer’s patients [321] and T cell abnormalities have also been identified in the blood and cerebral spinal fluid of Alzheimer’s patients [104, 212]. Studies in a mouse model have also shown that β-amyloid promotes T cell infiltration, and it interferes with proper T cell functioning, including activation and antigen presentation, suggesting that failure to mount a protective immune response may contribute to AD pathology [95]. A breakdown in antigen presentation may contribute to an immune inability to clear β-amyloid. Alterations in the peripheral lymphocyte profiles have also been demonstrated in Alzheimer’s disease [49, 50, 184, 262]. Recently, studies have also shown an association between higher levels of CD 4+ T-cell counts and an increased risk of AD [90]. Most research has focused on T cells in AD, but a few recent findings have also highlighted the roles of B cells in the disease. One study suggests that B cell depletion may prevent disease progression, which is an interesting theory in light of recent identification of resident B cells in the dura mater [171, 275]. This data suggests that alterations in B lymphocyte number, subsets, and production of autoantibodies may all be involved in AD pathology and progression of the disease [33, 270, 271, 298].

Recent studies focusing on cerebrospinal fluid (CSF) biomarkers have consistently disregarded the cellular infiltrates, treating them as artifacts of collection. However, a careful examination of CSF by cutting-edge methods of mass cytometry, revealed a consistent increase in CD8+ T-effector memory CD45RA+ (TEMRA) cells, and their association with cognitive impairment [104]. Additionally, single-cell RNA sequencing and artificial intelligence revealed an increase in T cell receptor (TCR) signaling, and further analysis identified clonally expanded CD8+ TEMRA cells targeting Epstein–Barr viral antigens. These studies show that T cells in the CSF play the same role as peripheral T cells in surveillance and maintenance of the intrathelial space. The existence of immune plasticity can be both beneficial and detrimental, depending on the target, extent of activity, and resolution of the inflammatory cascade [172, 278]. This complex pathway is consistent with findings showing that depletion of T cells prevents hippocampal infiltration and spatial memory deficits in AD models [186]. Acute inflammatory responses may be neuroprotective
and promote plaque clearance, but chronic inflammatory responses may be detrimental due to excessive collateral tissue damage [4, 273]. Therefore, lymphocyte physiology is altered during AD pathogenesis and these changes likely play a role in the progression of the disease.

Immunotherapy is an area of high interest in AD. The recent approval of a monoclonal antibody called aducanumab that selectively targets aggregated forms of amyloid β in AD patients may help in preventing early disease progression [94, 277, 282]. This antibody is produced using selectively reactive B cells, and shows that the adaptive immune system may hold the key for better AD treatments and prognoses. However, the approval of aducanumab has been met with controversy and many questions arose about the efficacy of this drug [173, 282]. While the clinical success of aducanumab remains in question, immunotherapy using other antibodies will continue to be the focus of research for future drug development in this field. Overall, research involving monoclonal antibodies that recruit T cells (e.g., effector T cells and Tregs) to target amyloid β may hold promise in restoring the disrupted immune balance in AD.

**Adaptive immunity and Parkinson's disease**

Parkinson's disease (PD) is another example of an inflammatory disease process causing progressive neurodegeneration of the dopaminergic neurons in the substantia nigra of the brain [20]. Aggregates of misfolded α-synuclein (α-syn protein) accumulate in the brain of PD patients, similar to the protein aggregates observed in Alzheimer's disease. Patients suffering from PD experience motor symptoms such as tremors, muscle rigidity, and slowness of movement (bradykinesia) but they can also experience cognitive impairment. The involvement of immune cells in PD has been suggested. For example, studies have shown activated microglia in the substantia nigra of postmortem Parkinson's disease patients [207] and potential role of the adaptive immune system in PD has been shown [132, 163, 250].

Parkinson's disease is considered to be a systemic inflammatory disorder because elevated pro-inflammatory cytokines are found in the blood of PD patients [27, 79, 103, 140, 257, 259, 304]. An increased level of inflammatory cytokines is believed to be due to T cell activation. Studies have shown that activation of T cells in response to Parkinsonian α-synuclein peptides and the inflammation observed in PD could be, partly, due to the involvement of autoreactive T cells [23, 307]. Autoreactive T cells are central to autoimmune pathology, so their presence may suggest the disease is autoimmune in nature. Autoimmune conditions are also characterized by the creation of autoantibodies by B cells against self-antigens which has been demonstrated in the peripheral blood of PD patients [83, 235, 347]. Recently, a study has shown an alteration in B cells population, which may play a role in PD [332]. Additionally, studies have also shown abnormal profiles of B cells and T follicular cells, indicating a polarization towards an inflammatory phenotype [195].

Regardless of the autoimmune nature of Parkinson's disease, T cells, and the adaptive immune system are believed to contribute to the disease development [132, 163, 250]. Several studies reported a Th1 bias in PD patients and experimental animal models [15, 53, 181]. As Th1 cells are pro-inflammatory, a shift favoring their expansion is congruent with the theory that neuroinflammation plays a role in PD. Another study has shown that CD4+ cells were the primary mediator of dopaminergic damage [31], while other studies have shown a decrease in the circulating CD4+ cell population in PD [18, 301]. If CD4+ T cells are the main mediators of disease, decreased circulating levels seem contradictory. However, the overall decrease in CD4+ T cells may be attributed to a decrease in Th17, Th2, and Treg cells and not the Th1 lineage [181]. Maintenance of the Th1 lineage despite a decrease in the other subsets would still fit with the studies citing a Th1 bias, though not all studies are in agreement [229]. One study marked an observed increase in the proportional CD4+ and CD3+ T cells as well as the CD4+/CD8+ ratio in PD patients [52]; whereas, another study showed a decrease in the CD3+, CD8+ T cells and B lymphocyte subsets in addition to a decrease in CD4+ T cells [114, 229]. Reasons for a decrease in the CD4+ T cell population may be explained by a study done by Calopa et al. which found increased susceptibility to apoptosis in the CD4+ T cells in the peripheral blood of PD patients [34]. Other conflicting data exist on the Th17 subset. While Kustrimovic et al. found that Th17 cells were decreased in the blood of PD patients, other studies have found that peripheral Th17 cells were increased in PD patients [49, 50, 53, 349]. There is conflicting evidence on the relative prevalence of each subset level, but overall, many abnormalities in T cells subsets populations have been reported in PD in favor of an inflammatory phenotype. More research is needed to clarify how effector T cell populations are affected in PD.

Treg cells likely play an opposing role in PD to the inflammatory T cell subsets by suppressing their effector functions and preventing rampant inflammation [139]. This hypothesis is supported by studies that showed that the transfer of Treg cells could provide neuroprotection in mouse models of PD [260, 261]. The beneficial nature of Treg cells in PD may explain why global T cell deficiency worsened the motor deficits seen in a Parkinson mouse model by decreasing effector T cells and inadvertently reducing the protective effects of Treg cells [340].
However, as PD is plagued by neuroinflammation, it is evident that Treg cells cannot properly execute their job for unknown reasons, and this dysfunction may contribute to disease progression [165]. The idea that Treg cells are unable to adequately function is supported by a study that has shown an impaired ability of Treg cells to suppress effector T cells in PD [274]. This breakdown of functioning furthers the theory that an inflammatory imbalance is observed in PD. In spite of discrepancies relating to T cell subset numbers, a change in the ability of Treg cells to function properly would result in homeostatic deviations regardless of cell numbers. More research is needed to clarify the uncertainties in the field, but most of the literature available suggests that the inflammation observed during PD is partly due to a T cell subset imbalance, which favors inflammation [52, 196]. Better understanding of the mechanisms behind PD and how the immune system is involved will hopefully lend to the development of effective therapies for PD.

Adaptive immunity and multiple sclerosis

Multiple sclerosis (MS) is another neurodegenerative disease of the central nervous system that causes motor and sensory deficits [245]. The main hallmark of the disease is the presence of disseminated focal lesions or plaques in the CNS where demyelination and gliosis occur with relative axonal sparing [247]. Multiple sclerosis is an inflammatory disease similar to other neurodegenerative conditions, with macrophages and microglia contributing to the pathology. Other peripheral immune cells are also likely to be involved in the demyelination, including T cells (CD4+ and CD8+), B lymphocytes, plasma cells, and dendritic cells [75, 129], and interactions between macrophages and lymphocytes may be part of the underlying pathogenesis [58].

Autoreactive T cells are an important part of autoimmune pathology in MS. Due to the extensive involvement of lymphocytes in MS plaques, the question has been raised as to whether the cause of the inflammation observed in MS may be autoimmune-dependent. A widely used animal model of MS, known as experimental autoimmune encephalomyelitis (EAE), is largely CD4+ T cell-driven [60]. Moreover, data have shown a link between CD4+ cytotoxic lymphocytes, disease severity, and plaque activity in MS patients [102, 241]. Despite haziness surrounding the underlying cause of the inflammation seen in MS, the evidence of T cell involvement is strong. It has been shown that activated T cells can induce experimental autoimmune encephalomyelitis in healthy mice [97, 177, 209] and that global reduction of most lymphocytes via alemtuzumab can improve MS pathology [161, 249]. Th1 cells have been implicated as important detrimental players in MS due to their ability to stimulate M1 macrophages through the secretion of TNF-α and IFN-γ, which are important mediators of inflammation and cellular damage [192]. Most of the earlier research in MS focused on the role of T cells, however, recently researchers have also acknowledged a cooperation between B cells and T cells in MS pathogenesis [155]. For example, B cells have been shown to work in tandem with T cells in human MS pathology [155]. Though more research is needed on the interplay between T cells and B cells in multiple sclerosis, a similar shift towards a pro-inflammatory B cell state has been suggested [85, 86, 193, 194]. The mechanisms involved in B cell-induced pathology in MS remains largely unknown. As of 2019, all approved MS disease-modifying therapies impact B cells in some way, such as depletion of CD20 + B cells [270]. However, not all B cell targeted therapies in MS have created positive results. One clinical trial using an experimental B cell depleting therapy for MS was terminated early due to worsening of disease progression [164]. This suggests that the role of B cells in MS is complex, and more research is needed to better understand the exact roles of B cells in MS pathology.

Unlike the harmful effects of the inflammatory T cell subsets discussed, Treg cells are likely protective in MS. For example, the transfer of myelin oligodendrocyte glycoprotein specific Treg cells displayed dose-dependent protection against experimental autoimmune encephalomyelitis [175, 258]. Inflammation in MS pathology may be in part due to a decrease in Treg cells, [136, 248] or functionality [92, 120, 179, 211, 326]. A reduced capacity of naive CD4+ T cells to differentiate into Treg cells under pathological conditions has also been demonstrated [281]. A reduction in number or function of Treg cells would mean a decreased capacity for inflammatory suppression. On the other hand, some studies have shown relative increases in the levels of Treg cells in MS [92, 179], but reduced functionality [179]. This may suggest Treg cells functionality may be more consequential in MS pathology than the number itself. Although more research is needed to clarify how each subset of T cells is involved in MS, current data suggest that a failure in Treg cell number and or functioning combined with an upregulation of effector T cells contribute to the inflammatory and CNS damage seen in MS [211]. A deeper understanding of T cells interaction within MS will hopefully lead to new therapy. Interventions that downregulate effector T cells or upregulate Treg cells may decrease the disease progression in MS patients.

Adaptive immunity and the eye

The eye is an “immune privileged” organ, which limits its inflammatory immune response so that vision is not harmed by swelling, infection, and other tissue
changes. The eye is similar to the brain, testes, placenta, and fetus in regard to immune responses. Typically, even foreign antigens do not trigger immune responses in these organs. In addition, the blood–retinal barriers in the eye stop infiltration of blood-borne pathogens and immune cells under physiological conditions. However, under pathological conditions such as uveitis, glaucoma, diabetic retinopathy, and retinal ischemia, numerous immune cells can infiltrate the eye and may induce or facilitate autoimmune that can lead to the development of autoimmunity [38].

In general, if an immune-privileged organ is damaged, previously insulated proteins will be exposed to peripheral immune cells that have not encountered these “novel” antigens. Having never come across these antigens before, peripheral immune cells have not learned to recognize them as self, allowing the generation of autoreactive lymphocytes [99]. The immune-privileged status of the eye is maintained by the blood–retinal barrier’s passive physical sequestration via tight junctions and the retinal pigment epithelium. The protective microenvironment of the eye is immunosuppressive and it expresses substances such as Qa-1, Fas ligand, and indolamine 2,3-dioxidase (IDO) which function to prevent a damaging inflammatory reaction to ocular tissues [61]. The immunosuppressive environment is also influenced by the aqueous humor which dampens the activity of many immune responses including nitric oxide production by macrophages [310], complement activation [111], neutrophil activation [303], lymphocyte proliferation [162], and NK cell activity [10]. Treg cells are also involved in the immune privilege of the eye through anterior chamber-associated immune deviation [13], in which injection of a foreign antigen into the anterior chamber of the eye causes an antigen-dependent downregulation of delayed-type hypersensitivity [324]. Overall, these mechanisms create an environment that is sheltered from potential immune cell-induced injury [227].

**Adaptive immunity and uveitis**

Typically, uveitis is classified by the affected anatomical part of the eye (e.g., anterior uveitis, intermediate uveitis, posterior uveitis and panuveitis) [17, 191]. Often the cause of uveitis is idiopathic, but sometimes an infectious cause (e.g., toxoplasmosis, tuberculosis, onchocerciasis, cysticercosis, leprosy and leptospirosis) can be responsible for this disease [70, 71]. Non-infectious uveitis is immune mediated and can be limited to the eye (e.g., sympathetic ophthalmia and birdshot retinochoroidopathy) or part of a broader systemic disease (e.g., sero-negative HLA-B27-positive spondyloarthropathies, juvenile idiopathic arthritis, sarcoidosis, multiple sclerosis, inflammatory bowel disease, tubulointerstitial nephritis, Behçet disease, and Vogt–Koyanagi–Harada syndrome) [39, 71]. Ongoing research proposes that noninfectious uveitis may be an autoimmune condition through breakdown of self-tolerance and mobilization of autoreactive effector cells. However, there are some theories in the field suggesting some cases of idiopathic immune-mediated uveitis might be the result of reactive infectious agents concealed in ocular tissue rather than true autoimmunity [98]. Nevertheless, autoimmune pathogenesis is generally accepted as a contributing factor in uveitis [17]. Support for the autoimmune theory of uveitis is provided by the increased genetic susceptibility of people with certain HLA phenotypes, as HLA genes have long been linked to autoimmunity [205]. In addition, autoimmune conditions are characterized by autoreactive T cells targeting self-antigens, evidence of which has been demonstrated in patients with noninfectious uveitis with uveal melanin, retinal arrestin, and inter-photoreceptor retinoid binding protein (IRBP) [39]. The experimental autoimmune uveitis (EAU) mouse model of posterior uveitis has demonstrated reduced inflammation through anti-CD3-mediated T cell suppression [306]. Interestingly, another study that used an anti-CD3 antibody saw a decrease activation of effector T cells but enhanced activation of Treg cells [168]. The autoreactive T cells responsible for autoimmune pathology were thought to be Th1 CD4+ T cells [80, 100], but more recent studies have indicated both Th1 and Th17 cells can contribute [133, 337]. Most research implicates both Th1 and Th17 in uveitis pathology, but other subsets may also be involved as well, such as a small subset of T cells known as γδ T cells [66, 283]. Some studies have also reported the possibility of autoreactive CD8+ T cells involvement in uveitis [210, 283, 300]. It is also possible that the etiology may vary between the different conditions and the stages of uveitis. For example, in Behçet’s uveitis there is a greater number of CD8+ T cell in the aqueous humor [356], but in sarcoid uveitis the CD4+/CD8+ ratio was increased [69]. These discrepancies suggest a possible difference in the pathogenesis between uveitis etiologies which could also affect their treatment approaches. There is still a lot to be done to fully clarify the role of CD8+ T cells in uveitis pathology, but there is mounting evidence that CD8+ T cells participate in autoimmune disease, making it plausible that they contribute significantly in uveitis pathology [76, 350]. Despite some remaining ambiguity, there is substantial support that Th1 cells and Th17 cells are implicated in autoimmune pathology [7, 115, 200, 308]. The specific role of each T cell subset in uveitis requires additional research that will fill in the gaps in our knowledge.
Most of the studies have focused on the roles of T cells, but B lymphocytes also likely play roles in uveitis. B lymphocytes may promote an inflammatory environment as well as promote T cell survival [296]. For example, depletion of B lymphocytes by rituximab and other monoclonal antibodies treatment in uveitis provides positive outcomes [68, 128, 214]. In contrast, some studies also have shown protective effects of B lymphocytes. For example, B lymphocytes suppressed intraocular inflammation and helped expand protective Treg cells in a mouse model [55]. Additionally, loss of a transcription factor in B cells caused suppression of both B regulatory and T regulatory cells, which resulted in worsening of the disease [232]. This suggests that certain B cell subsets may be contributing to uveitis pathology, while others may be protective.

Studies have shown that regulatory T (Treg) cells in uveitis have the ability to modulate inflammation and downregulate effector immune functions. The unregulated inflammation seen in uveitis suggests aberrant activation or a breakdown in proper Treg cell functionality or number. This idea was supported by a study done by Muhammad et al. that showed reduced ability to induce Treg cells in the experimental autoimmune uveoretinitis model [220, 333, 334]. In addition, a reduction in Treg cells has been shown in patients with active uveitis [269, 354] and Behçet’s disease before an ocular attack [222] in peripheral blood samples. Dysregulation of Treg cells has also been shown as a contributing factor for disease recurrence in recurrent experimental autoimmune uveitis [167]. Additionally, in a mouse model of experimental autoimmune uveitis adoptive transfer of Treg cells has been shown to suppress disease progression [290]. This idea is further supported by a study that claims a shift away from an inflammatory T cell phenotype in favor of Treg cells help mediate disease resolution [108]. Silver et al. also implicate Treg cells in the resolution and remission of uveitis pathology, although they claim Treg cells functionality is not impaired under pathologic condition [293]. This is a direct contradiction of what Ke et al. state when they claim that dysregulation and improper function of Treg cells contribute to disease recurrence [167]. Nevertheless, despite this discrepancy in whether Treg cells are decreased in number only or also in functionality, promoting the proliferation of Treg cells results in the suppression of pathology. These studies implicate Treg cells dysfunction during the development of uveitis. Moreover, a deficiency of Treg cells (e.g., function, numbers) may play a central role in disease pathogenesis. More research is needed to clarify how the population of Treg cells changed during the progression of uveitis.

Adaptive immunity and diabetic retinopathy

Diabetic retinopathy is one of the leading causes of blindness in human between the ages 27 and 75, and its estimated prevalence is 90% for patients who have had diabetes for over 20 years [41]. Chronic poor glucose control along with diabetes can lead to vascular complications such as macular edema, neovascularization, and microaneurysms which result in the loss of central vision in diabetic retinopathy patients [188]. As the incidence of diabetes continues to rise, the number of people suffering from diabetic retinopathy is expected to rise as well [295]. Many factors contribute to the development of diabetic retinopathy, but this perspective review will provide limited information for the role of T cells in the diabetic retinopathy.

Inflammation has been linked to obesity and metabolic disorders such as diabetes [134, 338]. Many pro-inflammatory cytokines have been shown to be elevated in the vitreous humor of patients with diabetic retinopathy including TNF-α [366], IL-8 and MCP-1 [130], IL-6 [119], IL-26 [333, 334] and IL-1β [366]. Studies have also shown that more Th1-dependent pro-inflammatory cytokines are secreted in diabetic retinopathy, suggesting an imbalance of lymphocytes [36]. An important part of diabetic retinopathy pathology is blood vessel angiogenesis which is promoted by vascular endothelial growth factor (VEGF). However, studies have shown that the Th1/Th2 ratio is an independent predictor of VEGF plasma levels in diabetic retinopathy [363]. Other studies suggest that Th17 cell-dependent IL-17 may be associated with the inflammation observed in diabetic retinopathy [46, 48, 148]. IL-17A has been shown to be an important detrimental cytokine in the progression of diabetic retinopathy [253, 254]. Studies have also shown that Th17 cells can infiltrate the retina in a diabetic retinopathy mouse model [291]. Moreover, elevated levels of IL-17 have been identified in the plasma [124], vitreous [151], and aqueous humor [93], of diabetic retinopathy patients. However, conflicting data exist on the level of IL-17 in the serum of diabetic retinopathy patients because studies have also shown a negative association with IL-17 and diabetic retinopathy [3, 221].

The overwhelming inflammation seen in diabetic retinopathy may be due to an imbalance of Treg cells. For example, studies have shown decreased numbers of Treg cells in type II diabetes and diabetic retinopathy patients [251, 351, 358]. Treg cells have also been shown to be beneficial in repairing abnormal angiogenesis in diabetic retinopathy [74]. In addition to the disturbance in the homeostasis of effector T cells and the population of Treg cells, Treg cells functions could also be altered by the surrounding environment. For instance, Treg cells may be unable to properly suppress inflammation in diabetic...
retinopathy due to elevated insulin levels [123]. Treg cells have been shown to have reduced suppressive capacity in type II diabetes mellitus patients [285]. Additional studies are required to clearly understand the neuroprotective role of Treg cells in diabetic retinopathy.

**Adaptive immunity and age-related macular degeneration**

Age-related macular degeneration (AMD) is a progressive disease-causing degeneration of the macula and is the leading cause of blindness among the elderly population in developed countries [344]. Two different pathologic components contribute to vision loss in AMD: focal atrophy of the retinal pigment epithelium (RPE) and photoreceptor loss ("dry" AMD) or choroidal neovascularization ("wet" AMD) [322]. Typically, dry AMD is a precursor for wet AMD, but not all patients will experience both [8]. In dry AMD, there is a gradual expansion of the atrophic lesions and a slow progressive vision loss. In wet AMD, the new blood vessels leak leading to edema, retinal damage, and can cause a rapid loss of visual acuity. Currently, there is no approved drug therapy to treat dry macular degeneration, though there are many ongoing clinical trials to address this problem [238]. Some clinical progress has been made to treat wet AMD, such as anti-VEGF therapy that targets VEGF, an important growth factor that facilitates angiogenesis [170]. However, anti-VEGF therapy only delays disease progression and upon treatment cessation relapse is a common problem [333, 334]. An important component of AMD is persistent inflammation [239]. Elevated levels of complement proteins have been detected in the blood samples of AMD patients, suggesting some sort of complement dysfunction may be contributing to the disease [126, 202, 263]. The current understanding of AMD is that local complement dysregulation is involved in the disease pathogenesis. One component of complement called complement factor H (CFH) is an important inhibitor of the alternative pathway of complement, and CFH polymorphisms have been linked to an increased risk of AMD development [88, 183]. Despite the abundance of genetic evidence linking complement to AMD, the exact role of how complement may be involved is still not clear.

Studies in an AMD mouse model have shown that T cells can contribute to AMD pathogenesis [65]. Patients with neovascularization AMD were also shown to have higher systemic lymphocyte counts, suggesting that lymphocytes may play an active role in initiating the neovascularization seen in AMD. [305]. Several studies found that the neutrophil-to-lymphocyte ratio (NLR), which are thought to be a marker of both inflammation and angiogenesis, were elevated in wet AMD [147, 225, 309]. These studies suggest that immune cells may be dysfunctional in neovascular AMD, however, the clinical relevance remains unclear [225]. In addition, increased recruitment of T cells in AMD has also been shown [216, 224]. Studies have also shown dysfunction or senescence of the immune system in the context of aging and neurodegenerative disease through the creation of a chronic state of low-grade inflammation referred to as “inflammaging” [73, 101]. This state of immune senescence has been implicated in AMD in which T cells are likely involved [190]. Additionally, several studies have shown an increased proportion of aged T cells in AMD patients, suggesting that immune dysfunction may play a role in disease pathogenesis [89, 305]. Dysregulation of follicular T cells has also been reported in AMD [345]. The idea of T cells dysregulation is further supported by a study showing alterations in systemic Th1 lymphocyte profiles in AMD patients [294]. More specifically, studies have shown that IL-17 may be an important part of AMD disease development [11, 288] since reducing IL-17 levels decreased the amount of choroidal neovascularization [125, 197]. However, unlike other diseases previously discussed in this review, the main source of IL-17 in AMD may not be from Th17 cells, but instead from γδ T cells [365]. These IL-17 producing γδ T cells have been shown to infiltrate the eye in a mouse model of choroidal neovascularization (CNV) [64]. Notably, IL-17 + cells have also been identified near areas of RPE atrophy [35]. Another mouse model study showed that Th2 cytokines, mainly IL-4, helped to decrease neovascularization in the disease process [346]. This supports the overall theory that an imbalance in the pro/anti-inflammatory phenotypes helps to drive AMD. Limited data have shown an increase in Th17 and Th1 cells in AMD patients [49, 50], whereas another study has shown a decrease in Th1 cells and no significant changes in Th17 cells [294]. Interestingly, one study found that decreased levels of CD4+ T cells correlated with the absence of subretinal fibrosis in AMD [187]. Overall, more studies are needed to better understand the role of adaptive immune cells in AMD.

Limited literature exists for the involvement of B lymphocytes in AMD, but anti-retinal antibodies have been identified in AMD patients [2, 118, 146, 217, 243]. It remains in question whether they are a consequence of disease-related damage or a contributory factor for the disease development [157, 158, 160]. In contrast, studies have also shown no difference in the number of circulating B lymphocytes in AMD patients when compared with healthy subjects, which does not rule out B lymphocytes involvement in AMD pathology because antibody production by B lymphocytes could still have a contributory effect [46, 48]. Studies have also suggested that autoantibodies could be used as biomarkers for future disease progression and prognostication [157, 158, 160, 218].
Another study found elevated levels of IL-17 correlated with response to anti-VEGF therapy [223]. Identification of a biomarker could have great clinical significance in AMD treatment, however more work is needed in this area.

Retina repair and reduced angiogenesis were observed through adoptive transfer of Treg cells and Treg cells expansion [74]. Currently, not many studies have looked at the role of Treg cells in AMD. One study did not find changes in the number of systemic Treg cells in AMD [203]. Like effector T cells and B cells, it is again possible that Treg cells dysfunction may play larger roles than Treg cells number [19]. Treg cells are a promising candidate to study in inflammatory diseases, and they may be implicated in AMD, though more research is needed.

Adaptive immunity and glaucoma

Glaucoma is the second leading cause of blindness worldwide in which retinal ganglion cells (RGCs) die slowly and progressively over a prolonged period of time. Glaucoma is now considered to be a multifactorial disease and molecular mechanisms involved in RGC death are complex and poorly understood [28, 109, 226, 325]. The primary risk factor for developing glaucoma is elevated intraocular pressure (IOP), but the pathophysiology of the disease is more complicated [22, 59, 84, 127, 299]. There is currently no known cure for glaucoma and treatment focuses on reducing IOP [47]. Unfortunately, some patients under IOP-lowering therapy still see progression of the disease, which clearly indicates that better therapeutic options are needed to fully cure the disease. Studies have shown that multiple factors play key roles in RGC degeneration including activation of caspases [44, 141, 142, 169, 208, 320], apoptosis [6, 116, 226, 255, 327], oxidative stress [56, 143, 150, 198, 219, 228, 272], ischemia and hypoxia [32, 57, 141, 141, 142, 142, 144, 234], epigenetic changes [105, 206, 242, 276, 353, 359, 359, 360, 360], Crosson 2010 #975, [145], alteration in the levels of pro-inflammatory cytokines [1, 312, 316, 341, 352, 357], and deprivation of neurotrophic factors [240, 256]. There is another opinion with limited evidence, which suggests the neurodegeneration observed in glaucoma could be vascular. This theory suggests that hemodynamic alterations and changes in local blood flow may cause unstable ocular perfusion to the optic nerve [42, 54, 96, 237, 355]. Recently, studies have also shown participation of T cells in glaucoma pathology. A study has shown that elevated IOP allowed for T cell infiltration of the retina and led to continued degeneration of RGCs after IOP was returned to a normal level [45, 51].

The innate immune system has long been tied to glaucoma through the action of glial cells and oxidative stress [201, 314, 319], but recent evidence provides additional support for the involvement of the adaptive immune system in glaucoma pathology [156]. Earlier studies have shown that glaucoma could be critically tied to the immune system because resistance of RGC death was shown to be correlated with immune potency [16]. This study suggested that immune dysfunction may be a prerequisite for developing glaucoma and would explain the disparities in degree of disease progression among patients treated with ocular hypertensive agents. Afterwards, numerous studies have shown the presence of autoantibodies to retinal and optic nerve proteins in the serum [21, 77, 159, 204, 264, 313, 317, 348], retina [112], and aqueous humor [157, 158, 160] of glaucoma patients. Studies have also shown the presence of autoantibodies to heat shock proteins [26, 107, 318, 323, 336] in glaucoma. Heat shock proteins are a large family of molecular chaperones that can be upregulated in times of stress [213], but also have significant potential to induce molecular mimicry resulting in the creation of autoantibodies to host proteins [335]. In glaucoma, elevated levels of heat shock proteins such as HSP72 [318], HSP60, and HSP27 [315], have been reported, some of which may help facilitate RGC death [318, 330]. Introduction of heat shock proteins to rats through immunization can induce glaucomatous injury [45, 51, 336], but other studies have shown that induction of heat shock proteins can provide neuroprotection for RGCs [37, 236, 252]. Overall, the role of autoantibodies and heat shock proteins in glaucoma remains unclear. It is not clear if they are involved in glaucoma pathology directly, indirectly, or play a role in protective autoimmunity [364].

The involvement of T cells in glaucoma pathology remains in question, but we believe that T cell subsets, specifically the T effector/Treg cells homoeostasis, play a critical role in determining the fate of RGCs during glaucoma progression. Additionally, studies have shown an adoptive transfer of lymphocytes from glaucomatous mice into healthy mice stimulated RGC loss [113]. This causative effect suggests that adaptive immune dysfunction plays a direct role in the pathophysiology of glaucoma. Studies have shown that CD4+ T cells facilitate RGC death in an acute ischemia/reperfusion injury model [137]. An imbalance in Treg cells/Th17 cells in experimental autoimmune optic neuritis (EAON) has been shown, which shares key characteristics of glaucoma pathology [199]. Recent studies have also shown that transient elevation of IOP can cause T cells infiltration to the retina, leading to RGC degeneration [45, 51]. However, the role of Treg cells in glaucoma remains fully unexplored. The authors’ perspective in this regard is “enhanced neuroinflammation during glaucoma could be due to low number and/or function of Treg cells”. In other systems, unchecked inflammation has been attributed due to
improper functioning of Treg cells [343]. Adoptive transfer of Treg cells has shown promise in treating inflammatory conditions such as enteritis and multiple sclerosis suggesting it may prove an effective therapeutic option in glaucoma [87]. If under glaucomatous condition Treg cells are unable to differentiate, adoptive transfer of Treg cells may ameliorate the T cell imbalance and decrease inflammation. More work is needed in this field to better understand the involvement of T cells in glaucoma progression.

Conclusions
We provided a brief overview of adaptive immunity, autoimmunity, and tolerance and related them to neurodegenerative and ocular diseases. This perspective review article aims to emphasize the significance of adaptive immunity concerning neurodegenerative conditions and highlight the gaps in the field. It also highlights the pathological and neuroprotective roles of different subsets of lymphocytes in numerous neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and several ocular diseases. Figure 1 provides a framework of potential contributing factors to neurodegenerative diseases. Although the etiology of each neurodegenerative disease is different and complex, a few common players that may have crucial roles in the pathology have been shown. These factors include neuroinflammation, epigenetic changes, ischemia/hypoxia, oxidative stress, hemodynamic alterations, and changes in the immune cells. The focus of this perspective review is to provide information for the role of immune cells (e.g., effector T and Treg cells) in neurodegenerative diseases. Based on the literature in non-ocular and ocular neurodegenerative diseases, we provided our perspective that: (1) the number of effector T cells may be increased under ocular pathologies such as uveitis, diabetic retinopathy, AMD, and glaucoma. Elevated T cells can subsequently enhance the secretion of pro-inflammatory cytokines and expedite retinal degeneration similar to other neurodegenerative diseases, and (2) Treg cells are deficient in function and/or number rendering them unable to sufficiently regulate the function of effector T cells in ocular pathologies as seen in other neurodegenerative diseases. Evidence of lymphocyte involvement in ocular pathologies is promising and there is a vital need for more research in this field. We conclude that T cell subsets homeostasis is critical for the maintenance and regulation of neuroinflammation. If the homeostasis is lost and the balance of specialized subsets of immune cells breaks down, damage to the host’s tissues can lead to pathological conditions. The inability to yet discover a neuroprotective therapy for ocular pathologies (e.g., uveitis, diabetic retinopathy, AMD, and glaucoma) it is highly desirable to target immune cells for future research.

Based on the literature provided in this perspective review article, we believe that in ocular neurodegenerative diseases, there may be an imbalance in the number of effector T cells as well as the number and or function of Treg cells, which might contribute to a pro-inflammatory state and facilitate neuronal death in such ocular diseases (e.g., uveitis, diabetic

![Fig. 1](image-url) Schematic showing the roles of numerous factors and immune cells in the induction or protection in neurodegenerative diseases
1. Abdul Y, Akhter N, Husain S. Delta-opioid agonist SNC-121 protects retinal ganglion cell function in a chronic ocular hypertensive rat model. Invest Ophthalmol Vis Sci. 2013;54(3):1816–28.

2. Adamus G, Chew EY, Ferris FL, Klein ML. Prevalence of anti-retinal autoantibodies in different stages of Age-related macular degeneration. BMC Ophthalmol. 2014;14:154.

3. Afzal N, Zaman S, Aghaer A, Javed K, Shahzad F, Zafar A, Nagi AH. Negative association of serum IL-6 and IL-17 with type-2 diabetes retinopathy. Iran J Immunol. 2014;11(1):40–8.

4. Agrawal A, Baulch J, Acharya M, Agrawal S. Identification of Peripheral immune mechanisms playing a protective role in Alzheimer’s Disease progression. J Immunol. 2019;202(1):182.136-182.136.

5. Alberts B, Johnson A, Lewis J, et al. The adaptive immune system. Molecular Biology of the Cell. New York, Garland Science. 2002.

6. Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res. 2012;31(2):152–81.

7. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13(6):711–8.

8. Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuroon. 2012;75(1):26–39.

9. Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626–35.

10. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998;160(2):5693–6.

11. Ardeljan D, Wang Y, Park S, Shen D, Chu XK, Yu CR, Abu-Asab M, Tuo J, Eberhart CG, Olsen TW, Mullins RF, White G, Wadsworth S, Scaria A, Chan CC. Interleukin-17 retinotoxicity is prevented by gene transfer of a soluble interleukin-17 receptor acting as a cytokine blocker: implications for age-related macular degeneration. PLoS ONE. 2014;9(4):e95900.

12. Arroyo-Hornero R, Hamad I, Corte-Real B, Kleinewietfeld M. The impact of dietary components on regulatory T cells and disease. Front Immunol. 2020;11:255.

13. Ashour HM, Niederkorn JY. Gammadelta T cells promote anterior chamber-associated immune deviation and immune privilege through their production of IL-10. J Immunol. 2006;177(12):8331–7.

14. Attias M, Al-Aubodah T, Piccirillo CA. Mechanisms of human FoxP3(+) Treg cell development and function in health and disease. Clin Exp Immunol. 2019;197(1):36–51.

15. Baba Y, Kuroiwa A, Utji RJ, Wsizolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005;11(8):493–8.

16. Bakalash S, Kipnis J, Yoles E, Schwartz M. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Invest Ophthalmol Vis Sci. 2002;43(8):2648–53.

17. Bansal S, Barathi VA, Iwata D, Agrawal R. Experimental autoimmune uveitis and other animal models of uveitis: an update. Indian J Ophthalmol. 2015;63(3):211–8.

18. Bas J, Calopa M, Mestre M, Mollevi DG, Cuillas B, Ambrosio S, Buendia E. Lymphocyte populations in Parkinson’s disease and in rat models of parkinsonism. J Neuroimmunol. 2001;113(1):146–52.

19. Behnke V, Wolf A, Langmann T. The role of lymphocytes and phagocytes in age-related macular degeneration (AMD). Cell Mol Life Sci. 2020;77(5):781–8.

20. Beitz JM. Parkinson’s disease: a review. Front Biosci (Schol Ed). 2014;6:65–74.

21. Bell K, Funke S, Pfeiffer N, Grus FH. Serum and antibodies of glaucoma patients lead to changes in the proteome, especially cell regulatory proteins, in retinal cells. PLoS ONE. 2012;7(10):e46910.

22. Bell K, Und Hohenstein-Blau NT, Teister J, Grus F. Modulation of the immune system for the treatment of glaucoma. Curr Neuropharmacol. 2018;16(7):942–58.

23. Bennet EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tispeorn V, Nemacheck C, Ciborowski P, Przedborski S, Mosley RL, Gendelman HE. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE. 2008;3(11):e1376.

24. Berg JM, TJ, Stryer L. Immune responses against self-antigens are suppressed. Biochemistry. New York, W H Freeman. 2002.
25. Berger A. Th1 and Th2 responses: what are they? BMJ. 2000;321(7258):424.
26. Beutgen VM, Perumal N, Pfeiffer N, Grus FH. Autoantibody biomarker discovery in primary open angle glaucoma using serological profile analysis (SERPA). Front Immunol. 2019;10:391.
27. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett. 1994;172(1–2):151–4.
28. Boland MV, Quigley HA. Risk factors and open-angle glaucoma: classification and application. J Glaucoma. 2007;16(4):406–18.
29. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohnsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28(16):4283–92.
30. Bondi MW, Edmonds EC, Salmon DP. Alzheimer's disease: past, present, and future. J Int Neuropsychol Soc. 2017;23(9–10):818–31.
31. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat M. Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis. 2010;38(1):1–7.
32. Buchi ER. Cell death in the rat retina after a pressure-induced ischaemia-reperfusion insult: an electron microscopic study. J Ganglion cell layer and inner nuclear layer. Exp Eye Res. 1992;55(4):605–13.
33. Bulati M, Buffa S, Martorana A, Gervasi F, Cambra C, Azzarellodi DM, Monastero R, Caruso C, Colonna-Romano G. Double negative (IgG+IgD-CD27-) B cells are increased in a cohort of moderate-severe Alzheimer's disease patients and show a pro-inflammatory trafficking receptor phenotype. J Alzheimers Dis. 2015;44(4):1241–51.
34. Calopa M, Bas J, Callen A, Mestre M. Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis. 2010;38(1):1–7.
35. Camelo S, Lavelette S, Guillonneau X, Raoul W, Sennlaub F. Association of choroidal interleukin-17-producing T lymphocytes and macrophages with geographic atrophy. Ophthalmologica. 2016;236(1):53–8.
36. Cao YL, Zhang FQ, Hao FQ. Th1/Th2 cytokine expression in diabetic patients. Cell Res. 2016;236(1):53–8.
37. Cao YL, Zhang FQ, Hao FQ. Th1/Th2 cytokine expression in diabetic patients. Cell Res. 2016;236(1):53–8.
38. Cao YL, Zhang FQ, Hao FQ. Th1/Th2 cytokine expression in diabetic patients. Cell Res. 2016;236(1):53–8.
39. Cao YL, Zhang FQ, Hao FQ. Th1/Th2 cytokine expression in diabetic patients. Cell Res. 2016;236(1):53–8.
40. Cebula A, Seweryn M, Rempala GA, Pabla SS, McIndoe RA, Denning L-C, Luis Miguel R-P, Ricardo Raúl R-R, Adolfo Daniel R-C. Oxidative stress and macrophages with geographic atrophy. Ophthalmologica. 2016;236(1):53–8.
41. Cebula A, Seweryn M, Rempala GA, Pabla SS, McIndoe RA, Denning L-C, Luis Miguel R-P, Ricardo Raúl R-R, Adolfo Daniel R-C. Oxidative stress and macrophages with geographic atrophy. Ophthalmologica. 2016;236(1):53–8.
42. Chaphalkar RM, Stankowska DL, He S, Kodati B, Phillips N, Prah J, Yang S, Dave N, Chevour P, Mahendradas P, Venkatesh A, Kawai A, Shetty R, Gosh A, Srinivas S. Increased aqueous humor CD4+ /CD8+ lymphocyte ratio in sarcoid uveitis. Ocul Immunol Inflamm. 2019;27(7):1033–40.
De Maio et al. Journal of Neuroinflammation (2022) 19:251
Page 13 of 19

70. de-la-Torre A, Lopez-Castillo CA, Rueda JC, Mantilla RD, Gomez-Marín JE, Anaya JM. Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia. Clin Exp Ophthalmol. 2009;37(5):458–66.
71. de Smet MC, Taylor SR, Bodagi B, Misrocchi E, Murray PI, Pleyer U, Zierzurt M, Baransi-Ansenbauer T, LeHoang P, Lightman S. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30(6):452–70.
72. De Ceglie S. Drug-induced autoimmunity. Curr Opin Rheumatol. 2009;21(5):547–51.
73. Deleidi M, Jaggle M, Rubino G. Immune aging, dysmetabolism, and inflammation in neurological diseases. Front Neurosci. 2015;9:172.
74. Deffa R, Taila DM, Zhu T, Maxwell JJ, Agostis A, Jerome JR, Hargreaves EM, Gerondakis S, Hibbs ML, Mackay F, Wilkinson-Berka JL. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nat Commun. 2017;8(1):748.
75. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–58.
76. Deng Q, Luo Y, Chang C, Wu H, Ding Y, Xiao R. The emerging epigenetic role of CD8+ T cells in autoimmune diseases: a systematic review. Front Immunol. 2019;10:856.
77. Dervan EW, Chen H, Ho SL, Brummel N, Schmid J, Toomey D, Haralamboys M, Bowne M, Gould E, Wallace DM, Prehn JH, O'Brien CJ, Murphy D. Protein macroarray profiling of serum autoantibodies in pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci. 2010;51(6):2968–75.
78. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neuropathol. 2019.14(1):32.
79. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. The neuropathological diagnosis of multiple sclerosis. Mol Neuropathol. 2019.14(1):32.
80. Dong C. Diversification of T-helper-cell lineages: finding the family roots of human T cells. Front Immunol. 2019;10:856.
81. Dorner T, Radbruch A. Antibodies and B cell memory in viral immunity. Nature. 2015;520(7544):298–307.
82. Dos Santos Picanco LC, Ozela PF, de Fatima de Brito Brito M, Pinheiro F. Double KL, Rowe DB, Carew-Jones FM, Hayes M, Chan DK, Blackie J, Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol. 2004;172(6):3422–7.
83. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim JY, Ougol J, Orgul S, Costa VP, Orzalesi N, Kriegstein GK, Serra LM, Renard JP, Stefansson E. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;21(4):359–93.
84. Fletcher J, Laksh J, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Curr Exp Immunol. 2010;162(1):1–11.
85. Forrester JV, Kuffova L, Dick AD. Autoimmunity, autoinflammation, and infection in uveitis. Am J Ophthalmol. 2018;189:77–85.
86. Forrester JV, Xu H. Good news-bad news: the Yin and Yang of immune activation and dysfunction in age-related macular degeneration. Front Immunol. 2019;10:856.
87. Foxman E, Zhang M, Hurst SD, Muchamuel T, Shen D, Wawrosek EF, Chan CC, Gery I. Inflammatory mediators in uveitis: differential induc- tion of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol. 2002;168(5):2483–92.
88. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invildia L, Celani L, Scutti M, Cevenini E, Castellani GC, Salvioni S. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105.
89. Frischer JM, Bramow S, Dal-Bianco A, Lucchetti CF, Rauschka H, Schmidbauer M, Laurens H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(Pt 5):1175–89.
90. Garretti F, Agulliu D, Lindestam Arlehamn CS, Sette A, Sulzer D. Autoimmu- nity in Parkinson's disease: the role of alpha-synuclein-specific T cells. Front Immunol. 2019;10:303.
91. Gate D, Saligramma N, Leventhal O, Yang AC, Unger MS, Middeldorp J, Chen K, Lehallier B, Chrannappa D, De Los Santos MB, McBride A, Pluninage J, Elahi F, Tam GK, Kim Y, Greicius M, Wagner AD, Agner L, Galasko DR, Davis MM, Wyss-Coray T. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. Nature. 2020;577(7790):399–404.
92. Gauthier AC, Liu J. Epigenetics and signaling pathways in glaucoma. Biomed Res Int. 2017;2017:5712341.
93. Geem O, Harusato A, Flanagan K, Denning TL. Harnessing regulatory T cells for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(6):1409–19.
94. Geyer O, Levo Y. Glaucoma is an autoimmune disease. Autoimmun Rev. 2020;19:2535.
95. Gilbert RM, Zhang X, Sampson RD, Ehrenstein MR, Nguyen DX, Chaudhry M, Mein C, Mahmud N, Galatowicz G, Tomkins-Netzer O, Calder VL, Lightman S. Clinical remission of sight-threatening non-infectious uveitis is characterized by an upregulation of peripheral T-regulatory cell polarization towards T-bet and TGF-β. Front Immunol. 2018;9:907.
96. Goldblum D, Mittag T. Prospects for relevant glaucoma models in the future. Prog Retin Eye Res. 2020;102535.
97. Goldblum V, Lu W. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers (Basel). 2016;8(3):36.
98. Goslings WR, Prodeus AP, Streilein JW, Carroll MC, Jager MJ, Taylor AW. A small molecular weight factor in aqueous humor acts on C1q to pre- vent antibody-dependent complement activation. Invest Ophthalmol Vis Sci. 1998;39(6):989–95.
99. Gramlich OW, Beck S, von Thur Und N, Hohenstein-Blau N, Boehm A, Ziegler JM, Wetter NP, Grus FH. Enhanced insight into the autoim- mune component of glaucoma: IgG autoantibody accumulation and but not in the blood of multiple sclerosis patients. Curr Exp Immunol. 2007;147(3):412–8.
100. Feng S, Yu H, Yu Y, Geng Y, Li D, Yang C, Liu T, Li G, Yuan L. Levels of inflammatory cytokines IL-1β, IL-6, IL-8, IL-17A, and TNF-alpha in aqueous humor of patients with diabetic retinopathy. J Diabetes Res. 2018;2018:854623.
101. Ferrero J, Williams L, Stella H, Leitermann K, Mikuliks A, O’Gorman J, Sevigny J. First-in-human, double-blind, placebo-controlled, singlegroup escalation study of aducanumab (BIB0337) in mild-to-moderate Alzheimer’s disease. Alzheimers Dement (NY). 2016;2(3):169–76.
102. Forrester JV, Thomas M, Spani C, Gericke C, Schweizer N, Erzeng G, Engelhardt B, Kulic L, Suter T, Nitsch RM. T-cell brain infiltration and immature antigen-presenting cells in tiguncis models of Alzheimer's disease-like cerebral amyloidosis. Brain Behav Behav. 2016;5:211–25.
103. Forrester JV, Sutherland S, Phillips A. Human B cell subsets and implication in multiple sclerosis. J Immunol. 2004.172(6):3422–7.
pro-inflammatory conditions in human glaucomatous retina. PLoS ONE. 2013;8(2):e57557.

113. Gramlich OW, Ding QJ, Zhu W, Cook A, Anderson MG, Kuehn MH. Adop-
tive transfer of immune cells from glaucomatous mice provokes retinal
glia cell loss in recipients. Acta Neuropathol Commun. 2015;3:536.

114. Gruden MA, Sewell RD, Yanamandra K, Daviddova TV, Kuchery-
va L, Bocharov AR, Bocharova OA, Polyschuk W, Sherstnev VV,
Morozova-Roche LA. Immunoprotection against toxic biomarkers is
retained during Parkinson’s disease progression. J Neuroimmunol.
2011;233(1–2):221–7.

115. Guedes MC, Berengo LM, Proneca RD. Roles of interleukin-17 in uveitis.
Indian J Ophthalmol. 2016;64(9):628–34.

116. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal
vascular disease progression and suppression of autoimmune
diseases. Front Immunol. 2019;10:1988.

117. Gurne DH, Tiso MO, Edward DP, Rippol H. Antiretal antibodies in serum
of patients with age-related macular degeneration. Ophthalmology.
1991;98(5):602–7.

118. Gustavsson C, Agardh CD, Agardh E. Profile of intraocular tumour necro-
sis factor-alpha and interleukin-6 in diabetic subjects with different
degrees of diabetic retinopathy. Acta Ophthalmol. 2013;91(5):445–52.

119. Haas J, Hueb A, Viehover A, Fritzsching B, Falk CS, Filser A, Vetter T,
Kalkofen L, Korner P, Zajicek J, Haas J, Hueb A, Viehover A, Fritzsching B,
Falk CS, Filser A, Vetter T, Hammers CM, Stanley JR. Mechanisms of disease:
pemphigus and bullous pemphigoid. Annu Rev Pathol. 2016;11:175–97.

120. Hu J, Kugler A, Bieber T, Gruber G, Scholl HP, Pollok-Kopp B, Schmid-Kubista KE, Bailey KR, Charbel Issa P, Scholl HP, Pollok-Kopp B, Schmid-Kubista KE, Bailey KR, Oppermann M. Genetic control of the alternative pathway of comple-
mment in humans and age-related macular degeneration. Hum Mol
Genet. 2010;19(1):209–15.

121. Hecker LA, Edwards AO, Ryu E, Tosakulwong N, Burrows GG, Chou
YK, Boudette D, Ziegler SF, Offner H, Vandenbark AA. Decreased FOXP3
levels in multiple sclerosis patients. J Neurosci Res. 2005;81(1):45–52.

122. Hynes R, Boisserie E, Faucheux B, Brugg B, Mouat-Pregent A, Agid Y,
Hirsch EC. Nitric oxide synthase and neuronal vulnerability in Parkin-
son’s disease. Neuroscience. 1996;72(2):355–6.

123. Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target
for neuroprotection? Lancet Neurol. 2009;8(4):209–18.

124. Hotamisligil GS. Inflammation and metabolic disorders. Nature.
2006;444(7121):860–7.

125. Husain S, Abdul Y, Crosson CE. Preservation of retina ganglion cell func-
tion by morphine in a chronic ocular-hypertensive rat model. Invest
Ophthalmol Vis Sci. 2012;53(7):4289–98.

126. Husain S, Abdul Y, Potter DE. Non-analgesic effects of opioids: neuro-
protection in the retina. Curr Pharm Des. 2012;18(37):6101–8.

127. Husain S, Abdul Y, Singh S, Ahmad A, Husain M. Regulation of nitric
oxide production by delta-opioid receptors during glaucomatous
injury. PLoS ONE. 2014;9(10):e103937.

128. Husain S, Potter DE, Crosson CE. Opioid receptor-activation:
retina protected from ischemic injury. Invest Ophthalmol Vis Sci.
2009;50(8):3853–9.

129. Husain S, Zaidi SAH, Singh S, Guzman W, Mehrotra S. Reduction of
neuroinflammation by delta-opioids via STAT3-dependent pathway in
chronic glaucoma model. Front Pharmacol. 2021;12:601408.

130. Iannaccone A, Giorgianni F, New DD, Hollingsworth TJ, Umfress A,
Alhathem AH, Neeli L, Lenchil NL, Jennings BJ, Calaza JI, Satterfield M,
Mathews D, Diaz RI, Harris T, Johnson KC, Charles S, Kitchevsky SB, Ger-
lings KC, Beranova-Giorgianni S, Radic MZ, A B C s. Health. Circulating
autoantibodies in age-related macular degeneration recognize human macular tissue antigens implicated in autoagglutiny, immunomodula-
tion, and protection from oxidative stress and apoptosis. PLoS ONE.
2015;10(12):e0145323.

131. Ilhan N, Daglioglu MC, Ilhan O, Coskun M, Tuzcu EA, Kahraman H,
Keskin U. Assessment of neurophil/lymphocyte ratio in patients
with age-related macular degeneration. Ocul Immunol Inflamm.
2015;23(4):287–90.

132. Ip B, Cifone NA, Belkina AC, DeFuria J, Jagannathan-Bogdan M, Zhu M,
Kuchibhatla R, McDonnell ME, Xiao Q, Kepler TB, Apovian CM, Lauffen-
burger DA, Nikolajczyk BS. Th17 cytokines differentiate obesity from
obesity-associated type 2 diabetes and promote TNFalpha production.
Obesity (Silver Spring). 2016;24(1):102–12.

133. Ito JT, Cervilha DB, Loureiro JD, Goncalves NG, Volpini RA, Caldini EG,
Landman G, Lin CJ, Velosa APP, Teodoro WPR, Tibiero I, Mauad T, Martins
MA, Macchione M, Lopes F, Th17/Treg imbalance in COPD progression: a
temporal analysis using a CS-induced model. PLoS ONE. 2019;14(1):
e0209351.

134. Izzotti A, Bagnis A, Sacca SC. The role of oxidative stress in glaucoma.
Mutat Res. 2006;612(2):105–14.

135. Jagannathan-Bogdan M, McDonnell ME, Shin H, Rehman Q, Hasturk
H, Apovian CM, Nikolajczyk BS. Elevated proinflammatory cytokine
production by a skewed T cell compartment requires mono-
cytes and promotes inflammation in type 2 diabetes. J Immunol.
2011;186(2):1162–72.
152. Janeway CA Jr TP, Walport M et al. Principles of innate and adaptive
immunity. Immunobiology: The Immune System in Health and Disease
5th edition. New York, Garland Science. 2001.

153. Janeway CA Jr TP, Walport M et al. T cell-mediated cytotoxicity.
Immunobiology: The Immune System in Health and Disease. New York,
Garland Science. 2001.

154. Janeway CA Jr TP, Walport M et al. Antigen Recognition by T cells.
Immunobiology: The Immune System in Health and Disease New York,
Garland Science. 2001.

155. Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A,
Ruhmann S, Fairall W, Frankenhecht K, Pinilla C, Santos R, Hammer C,
Ortiz V, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A,
Khademi M, Olsson T, Pfeil F, Sospeseda M, Martin R. Memory B cells
activate brain-homing, autoreactive CD4(+)-T cells in multiple sclerosis.
Cell. 2018;175(1):85–100.e123.

156. Jiang S, Kameyama M, Chen DF. Adaptive immunity: new aspects of
pathogenesis underlying neurodegeneration in glaucoma and optic
neuropathy. Front Immunol. 2020;11:65.

157. Joachim SC, Bruns K, Lackner KJ, Pfeffer N, Grus FH. Analysis of IgG
antibody patterns against retinal antigens and antibodies to alpha-
crystallin, GFAP, and alpha-enolase in sera of patients with “wet”
age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol.
2007;245(5):619–26.

158. Joachim SC, Bruns K, Lackner KJ, Pfeffer N, Grus FH. Antibodies to alpha-
B-crystallin, vimentin, and heat shock protein 70 in aqueous humor of
patients with normal tension glaucoma and IgG antibody patterns against retinal antigen in aqueous humor. Curr Eye Res. 2007;32(6):501–9.

159. Joachim SC, Reichelt J, Berneser S, Pfeffer N, Grus FH. Sera of glaucoma
patients show autoantibodies against myelin basic protein and com-
plex autoantibody profiles against human optic nerve antigens. Graefes
Arch Clin Exp Ophthalmol. 2008;246(4):573–80.

160. Joachim SC, Wuessingh D, Pfeffer N, Grus FH. IgG antibody patterns in
aqueous humor of patients with primary open angle glaucoma and pneu-
moexfoliation glaucoma. Mol Vis. 2007;13:1573–9.

161. Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL,
Kaiser CJ, Ksander BR, Streilein JW. Inhibition of lymphocyte prolifera-
tion by aqueous humor. Reg Immunol. 1989;2(1):42–9.

162. Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD,
Karaaslan Z, Kahraman OT, Sanli E, Ergen HA, Ulusoy C, Bilgic B, Yilmaz
K, Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R,
Kermer P, Klocker N, Labes M, Thomsen S, Srinivasan A, Bahr M. Activa-
tion reverses progression of Alzheimer’s disease. Nat Commun. 2021;12(1):2185.

163. Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad
against retinal antigen in aqueous humor. Curr Eye Res. 2007;32(6):501–9.

164. Kipnis J, Mizrahi T, Hauben E, Shaked I, Shevach E, Schwartz M. Neuro-
protective autoimmunity: naturally occurring CD4+ and CD25+ regulatory
T cells suppress the ability to withstand injury to the central nervous
system. Proc Natl Acad Sci U S A. 2002;99(24):15620–5.

165. Knopfman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of
daucunabum: an analysis of the EMERGE and ENGAGE trials as reported
by Biogen, December 2019. Alzheimers Dement. 2021;7(14):696–701.

166. Koch S, Sopel N, Finotto S. Th9 and other IL-9-producing cells in allergic
asthma. Semin Immunopathol. 2017;39(1):53–68.

167. Kohr AP, Carpenter PA, Anger HA, Miller SD. Cutting edge: CD4+ and CD25+
regulatory T cells suppress antigen-specific autoimmune
immune responses and central nervous system inflammation during
active experimental autoimmune encephalomyelitis. J Immunol.
2002;169(9):4712–6.

168. Koonin EV, Krupovci M. Evolution of adaptive immunity from transpos-
able elements combined with innate immune systems. Nat Rev Genet.
2015;16(3):184–92.

169. Krenke-MA, Carlson TJ, Andjelicovski AV, Segal BM. IL-12- and IL-
23-modulated T cells induce distinct types of EAE based on histology,
CNS chemokine profile, and response to cytokine inhibition. J Exp Med.
2008;205(7):1353–41.

170. Kumar BV, Connors TJ, Farber DL. Human T cell development, localiza-
tion, and function throughout life. Immunity. 2018;48(2):202–13.

171. Kumar K, Putzi N, Linzer A, Remus R, Lindemann M, Knoop D,
Mueller N, Hardt C, Kreuzfelder E, Grosse-Wilde H. CD4+CD25+Fox3+ T
lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol.
2006;180(1–2):178–84.

172. Kumar P, Saini S, Khan S, Surendra Lele S, Prabhakar BS. Restoring self-
tolerance in autoimmune diseases by enhancing regulatory T-cells. Cell
Immunol. 2019;339:41–9.

173. Kustimovic N, Comi C, Magistrelli L, Rasini E, Legnaro M, Bombelli R,
Aleksic I, Blandini F, Minafra B, Riboldazzi G, Sturchio A, Mauri M, Bono
G, Marino F, Cosentino M. Parkinson’s disease patients have a complex
phenotypic and functional Th1 bias: cross-sectional studies of CD4+
Th1/Th2/Th17 and Treg in drug-naive and drug-treated patients. J Neu-
roinflammation. 2018;15(1):205.

174. La Paglia GMC, Leone MC, Legri G, Vagelli R, Valentini E, Alunno A, Tani
C. One year in review 2017: systemic lupus erythematosus. Clin Exp
Rheumatol. 2017;35(4):S51–61.

175. Landowski M, Kelly S, Uklebingere M, Grolee M, Ding JD, Grigsby D,
Bowes Rickman C. Human complement factor H Y402H polymor-
phism causes an age-related macular degeneration phenotype and
lipoprotein dysregulation in mice. Proc Natl Acad Sci U S A.
2019;116(9):3703–11.

176. Larbi A, Pavlecic G, Witkowski JM, Schipper HM, Derhovanessian E,
Goldeck D, Fulop T. Dramatic shifts in circulating CD4 but not CD8 T cell
subsets in mild Alzheimer’s disease. J Alzheimers Dis. 2009;17(1):91–103.

177. Lardo S, Soesastyo MH, Juffres G, Uppiyatti GR. The autoimmune mecha-
nism in dengue hemorrhagic fever. Acta Med Indones. 2018;50(1):70–9.

178. Laurent C, Dorothee H, Huniot S, Martin E, Monnet Y, Duchamp M, Dong
Y, Legeron FP, Lebuacher A, Burnous N, Saibre E, Carvalho K, Caillierez
R, Zommer N, Demeyer D, Jouy N, Sazдовitch V, Schraen-Maschke S,
Delaarce C, Buee L, Blum D. Hippocampal T cell infiltration promotes
neuropathology and cognitive decline in a mouse model of tsaupu-
athy. Brain. 2017;140(1):194–200.

179. Lechner J, Chen M, Hogg RT, Tho L, Silvestri G, Chakravarty U, Xu
H. Alterations in circulating immune cells in neovascular age-related
macular degeneration. Sci Rep. 2015;5:16754.

180. Lechner J, O’Leary OE, Sittw AW. The pathology associated with diabetic
retinopathy. Vision Res. 2017;139:397–14.

181. Lee GR. The balance of Th17 versus Treg cells in autoimmunity. Int J Mol
Sci. 2018;19(3):730.

182. Lee KS, Lin S, Copland DA, Dick AD, Liu J. Cellular senescence in the
aging retina and developments of senotherapies for age-related macu-
lar degeneration. J Neuroinflammation. 2021;18(1):32.

183. Legroux L, Arbour N. Multiple sclerosis and T lymphocytes: an entan-
glement. J Neuroimmunol. 2015;104(2):528–46.
193. Li J, Chen S, Xiao X, Zha Y, Ding W, Li XC. IL-9 and Th9 cells in health and diseases—from tolerance to immunopathology. Cytokine Growth Factor Rev. 2017;37:47–55.

194. Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomin PI, Antel J, Bar-Or A. Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis. J Immunol. 2017;198(2):691–8.

195. Li R, Tropea TF, Baratta LR, Zuroff L, Diaz-Ortiz ME, Zhang B, Shinoda K, Liu Y, You C, Zhang Z, Zhang J, Yan H. Roles of Treg/Th17 cell imbalance and diseases—from tolerance to immunopathology. Cytokine Growth Factor Rev. 2017;37:47–55.

196. Machalinski B. Elevated plasma levels of C3a complement component in the exudative form of age-related macular degeneration. J Immunol Res. 2014;1193:187–98.

197. Marrie RA, Banwell B, Bar-Or A. Abnormal effector and regulatory T cell profiles in patients with Parkinson’s disease: a cross-sectional study. Neurol Neuroimmunol Neuroinflamm. 2019;6(1):e2125.

198. Maruyama I, Ohguro H, Ikeda Y. Retinal ganglion cells recognized by T cell receptor (TCR) binding to MHC class II and T cell profiles in patients with parkinson disease: a cross-sectional study. Neurol Neuroimmunol Neuroinflamm. 2019;6(2):e2125.

199. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia Nigra of Parkinson’s disease brains. Neurology. 1988;38(8):1285–91.

200. McPherson SW, Yang J, Chan CC, Dou C, Gregerson DS. Resting CD8 T cell regulatory T cells recognize beta-galactosidase expressed in the immune-privileged retina and mediate autoimmune disease when activated. Immunity. 2003;10(3):386–96.

201. Mekhitiya J, Nyirenda MH, Li R, O'Mahony J, Rezk A, Rozenberg A, Moore CS, Johnson T, Sadowskii D, Collins DL, Arnold DL, Gran B, Yeh EA, Marini RA, Bawell B, Bar-Or A. Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. Brain. 2019;142(3):367–372.

202. Mietelska-Porowska A, Wójcik U. T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer’s disease: potential pools of new biomarkers. J Immunol Res. 2017;2017:74626540.

203. Miller DJ, Fort PE. Heat shock proteins regulatory role in neurodevelopment. Front Neurosci. 2018;12:827.

204. Miserocchi E, Pontikaki I, Mordorsii G, Bandello F, Meroni PL, Gerloni V. Rituximab for uveitis. Ophthalmology. 2011;118(1):223–4.

205. Mo C, Zeng Z, Deng Q, Ding Y, Xiao R. Immune balance between T helper 1 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosis. Biomed Pharmacother. 2018;108:177–83.

206. Mo FM, Proia AD, Johnson WH, Cui D, Lashkari K. Interferon gamma-inducible protein-10 (IP-10) and eotaxin as biomarkers in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51(8):4226–36.

207. Morohoshi K, Goodwin AM, Ohbayashi M, Ono SJ. Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. J Autoimmun. 2009;33(3–4):247–54.

208. Morohoshi K, Ohbayashi M, Patel N, Chung Y, Bird AC, Ono SJ. Identification of anti-retinal antibodies in patients with age-related macular degeneration. Exp Mol Pathol. 2012;92(3):193–9.

209. Mozaffarzadeh M, Grieshaber MC, Flammer J. Oxygen and blood flow: players in the pathogenesis of glaucoma. Mol Vis. 2008;14:224–33.

210. Muhammad F, Wang D, Montieth A, Lee S, Preble J, Foster CS, Larson TA, Ding K, Dvorak JD, Lee DJ. PD-1(–) melanocortin receptor dependent T cells prevent autoimmune disease. Sci Rep. 2019;9(1):16941.

211. Nadeem A, Javid K, Sami W, Zafar A, Jahan S, Zaman S, Nagi A. Inverse relationship of serum IL-17 with type-2 diabetes retinopathy. Clin Lab. 2013;59(11–12):1311–7.

212. Nakan Y, Kotake S, Goto M, Uijhara H, Matsubara M, Kamatani N. Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet’s disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol. 2016;26(4):354–8.

213. Nassar K, Grisanti S, Effar L, Luke J, Luke M, Grisanti S. Serum cytokines as biomarkers for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2015;253(5):699–704.

214. Newman AW, Gallo NB, Hancock LS, Miller NJ, Radeke CM, Maloney MA, Cooper JB, Hageman GS, Anderson DH, Johnson LV, Radeke MJ. Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks. Genome Med. 2012;4(2):16.

215. Niazi S, Krogh Nielsen M, Sørensen TL, Subhi Y. Neutrophil-to-lymphocyte ratio in age-related macular degeneration: a systematic review and meta-analysis. Acta Ophthalmol. 2019;97(6):538–66.

216. Nickells RW. Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Surv Ophthalmol. 1999;43(Suppl 1):S151–161.

217. Niederkorn JY. Immune privilege in the anterior chamber of the eye. Crit Rev Immunol. 2002;22(1):13–46.

218. Nita M, Gryzbowksi A. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxd Med Cell Longev. 2016;2016:3164734.

219. Niwa F, Kuriyama N, Nakagawa M, Imanishi J. Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson’s disease. Geriatr Gerontol Int. 2012;12(1):102–7.

220. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Matherette R, Mattson MP, Akbari V, LaFerla FM. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409–21.

221. Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45(2):344–55.

222. Oladipupo FG, Yu C-R, Olumuyide E, Jittisathorn Y, Choi JK, Egwuagu CE. STAT3 deficiency in B cells exacerbates uveitis by promoting expansion of pathogenic lymphocytes and suppressing regulatory B cells (Bregs) and Tregs. Sci Rep. 2020;10(1):16188.

223. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162–72.

224. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res. 2006;25(2):191–147.

225. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjiigeorgiou GM, Xiromerisiou G, Pavlidou K, Diamandopoulou M. STAT3 deficiency in B cells exacerbates uveitis by promoting expansion of pathogenic lymphocytes and suppressing regulatory B cells (Bregs) and Tregs. Sci Rep. 2020;10(1):16188.
Autoantibodies to alpha-synuclein in inherited Parkinson’s disease. J Neurochem. 2007;101(3):749–56.

236. Park KH, Ong OC, Caprioli J. Induction of heat shock protein 72 protects retinal ganglion cells in a rat glaucoma model. Invest Ophthal-mol Vis Sci. 2001;42(7):1522–30.

237. Park Y, Cho KJ. Choroidal vascular index in patients with open angle glaucoma and preperimetric glaucoma. PLoS ONE. 2019;14(3): e0213336.

238. Patel HR, Hariprasad SM, Eichenbaum D. Geographic atrophy: clinical impact and emerging treatments. Ophthalmic Surg Lasers Imaging Retina. 2015;46(9):13–18.

239. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol. 2008;30(2):97–110.

240. Peeters LM, Vanheusden M, Somers V, Van Wijmeersch B, Stinissen P, et al. Histone H4 deacetylation plays a critical role in early gene silencing during neuronal apoptosis. BMC Neurosci. 2010;11:62.

241. Penfold PL, Provis JM, Furby JH, Gatenby PA, Billson FA. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247(3):270–4.

242. Pereira LMS, Gomes STM, Ishak R, Vallinoto ACR. Regulatory T cell and CD4+CD25+ T cells drive multiple sclerosis progression. Front Immunol. 2017;8:605.

243. Pérez-Cerdá K, Sánchez-Gómez MV, Mateus C. The link of inflammation and neurodegeneration in progressive multiple sclerosis. Multi Sci Demyelinating Disorder. 2016;1(1):9.

244. Pietrinix K, Vaeth M, Schneider T, Beyersdorf N, Hunig T, Berberich-Siebell F, Lutz MB. Immature dendritic cells convert anergic nonregulatory T cells into Foxp3–IL-10+ regulatory T cells by engaging CD28 and CTLA-4. J Immunol. 2015;195(2):480–91.

245. Popescu BF, Firkö I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013;19(4):901–21.

246. Prakash S, Stouras P, Bednarki J, Vlckova E, Milukkova Z, Michalek J. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. J Neurol Sci. 2012;319(1–2):18–23.

247. Prosperini L, Annozzi P, Boffa L, Buscanin MC, Gallo A, Manna M, Maio M, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Grimaldi LME, Lonari A, Pugliatti F, Pucci E, Pasci M, Sarchielli P, G. Italian Alemtuzumab Study. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment in patients with multiple sclerosis: a 36-month real-world study. J Neurology. 2018;265(12):2851–60.

248. Qian L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J Neural Transm (Vienna). 2010;117(8):971–9.

249. Qiao YC, Shen J, He L, Hong XZ, Tian F, Pan YH, Liang L, Zhao XX, Zhao HL. Changes of regulatory T cells and of proinflammatory and immunosuppressive cytokines in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes Res. 2016;2016:3694957.

250. Qing Q, Duan X, Jiang Y. Heat shock protein 72 protects retinal ganglion cells in rat model of acute glaucoma. Yan Ke Xue Bao. 2005;21(3):163–8.

251. Qiu AW, Bian Z, Mao PA, Liu QH. IL-17A exacerbates diabetic retinopathy by impairing Muller cell function via Act1 signaling. Exp Eye Res. 2016;148(12):e280.

252. Qiu AW, Liu QH, Wang J. Blocking IL-17A alleviates diabetic retinopathy in rodents. Cell Physiol Biochem. 2017;41(1):960–72.

253. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res. 1999;18(1):39–57.

254. Quigley HA, Mc Kinnon SJ, Zack DJ, Pease ME, Kerrigan-Baumrind LA, Kerrigan DF, Mitchell RS. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthal-mol Vis Sci. 2001;42(11):3460–6.

255. Reale M, Jarolim C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofri M. Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun. 2009;23(1):55–63.

256. Reddy J, Illes Z, Zhang X, Encinas J, Pyrdol J, Nicholson L, Sobel RA, Wucherpfennig KW, Kuchroo VK. Myelin proteolipid protein-specific CD4+CD25+ regulatory T cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2004;101(43):15434–9.

257. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulos D. Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease. Acta Neurol Scand. 2007;116(6):374–9.

258. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol. 2007;82(5):1083–94.

259. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendel-man HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184(5):2261–71.

260. Rohrer B, Frazier-Abel A, Leonard A, Ratnapriya R, Ward T, Pietraszkiewicz A, O’Quinn E, Adams K, Swaroop A, Wolf BJ. Association of age-related macular degeneration with complement activation products, smoking, and single nucleotide polymorphisms in South Carolinians of European and African descent. Mol Vis. 2019;25:79–92.

261. Romano C, Barrett DA, Li Z, Petrouck A, Wax MB. Anti-rodopsin antibodies in sera from patients with normal-pressure glaucoma. Invest Ophthal-mol Vis Sci. 1995;36(10):1968–75.

262. Rose NR. Prediction and prevention of autoimmune disease in the 21st century: a review and preview. Ann J Epidemiol. 2016;183(5):403–6.

263. Rosenberg MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2288–33.

264. Rosenberg MD, Way SS, Abbas AK. Regulatory T cell memory. Nat Rev Immunol. 2016;16(2):90–101.

265. Rosso M, Chitnis T. Association between cigarette smoking and multiple sclerosis: a review. JAMA Neurol. 2019.

266. Ruggeri S, Frassanito MA, Dammacco R, Guerrino S. Treg lymphocytes in autoimmune uveitis. Mol Vis Sci. 2000;41(11):3460–6.

267. Sacca SC, Izzotti A, Rossi P, Traverso C. Glaucomatous outflow pathway resistance and oxidative stress. Exp Eye Res. 2007;84(3):389–99.

268. Salani F, Sterbini V, Sacchinielli E, Garamone M, Bossu P. Is innate memory a double-edge sword in Alzheimer’s disease? A reappraisal of new concepts and old data. Front Immunol. 2019;10:1768.

269. Saunders JA, Estes KA, Kosloski LM, Allen HE, Dempsey RM, Tomas-Rusotto DR, Meza JL, Santamaría PM, Bertoni JM, Murman DL, Ali HH, Standaert DG, Mosley RL, Gendelman HE. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson’s disease. J Neuroimmunol Pharmacol. 2012;7(4):927–38.

270. Schiffack D, Wolfert J, Heming M, Thomas C, Hartleinhert M, Borsch AL, Ricci A, Martín-Salamanca S, Li X, Lu BN, Pawlik M, Minnerup J, Streeker JH, Seidenbecher T, Meuth SG, Hidalgo A, Liesz A, Wiendl H, Meyer Zu Horste G. Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges. Nat Neurosci. 2021;24:1225.

271. Schmitt HM, Pezel HR, Schlamp CL, Nickells RW. Histone deacetylase 3 (HDAC3) plays an important role in retinal ganglion cell death after acute optic nerve injury. Mol Neurodegener. 2014;9:39.

272. Schneider L. A resurrection of aducanumab for Alzheimer’s disease. JAMA Neurol. 2019;76(12):1511–2.

273. Schwartz M, Baruch K. Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation. J Autoimmun. 2014;45:8–14.

274. Sebèna I, Pepper M. Humoral immune responses to infection: common mechanisms and unique strategies to combat pathogen immune evasion tactics. Curr Opin Immunol. 2018;51:46–54.
280. Serpente M, Bonni R, Scarpini E, Galimberti D. Innate immune system and inflammation in Alzheimer’s disease: from pathogenesis to treatment. NeuroImmunomodulation. 2014;21(2–3):79–87.
281. Severin ME, Lee PW, Liu Y, Selhorst AJ, Gomley-MG, Pei W, Yang Y, Guerai-de-Arellano M, Racke MK, Lovett-Racke AE. MicroRNAs targeting TGFbeta signalling underlie the regulatory T cell defect in multiple sclerosis. Brain. 2016;139(6):1747–61.
282. Slevogt J, Chiap P, Busseer T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chiolate TS, Brennan MS, Quintero-Moronz O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Fierro J, Jokl Y, Akins S, Grom J, Hock C, Nitsch RM, Sandrock A. The antibiotic aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016;537(7618):53–6.
283. Shao H, Sun SL, Kaplan HJ, Sun D. Characterization of rat CD8+ T cells for interphotoreceptor retinoid-binding protein (IRBP) epitope for autoreactive CD8+ T cells in the B10RIII mouse. J Neuroimmunol. 2008;193(1–2):68–76.
284. Stevens CH, Rowe D, Morel-Kopp MC, Orr C, Russell T, Ranola M, Ward C, Halliday GM. Reduced T helper and B lymphocytes in Parkinson’s disease. J Neuroimmunol. 2012;252(1–2):95–9.
285. Stojanovitch L, Mariashvilevitch D. Stress as a trigger of autoimmune disease. Autoimmun Rev. 2008;7(3):209–13.
286. Streilein JW, Stein-Streilein J. Does innate immune privilege exist? J Leukoc Biol. 2000;67(4):479–87.
287. Styppula G, Kunert-Radlek J, Stepien H, Zylinska K, Pawlikowski M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson’s disease. Neuroimmunomodulation. 1996;3(2–3):131–4.
288. Subhi Y, Lykke Sorensen T. New neoangiogenic disease associated with systemic leucocyte activity. Acta Ophthalmol. 2017;95(5):472–80.
289. Sugita S, Shimizu J, Makabe K, Keino H, Watanabe T, Takahashi M. Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody. Arthritis Res Ther. 2017;19(1):176.
290. Sulzer D, Alcalay RN, Garrett F, Cote L, Kanter E, Agin-Liebes J, Lioing C, McMurtrey C, Hildebrand WH, Mao X, Davison VL, Davison TM, Oseroff C, Pham J, Sidney J, Dillon MB, Carpenter W, Weiskopf D, Phillips E, Malal S, Peters B, Frazer A, Lindestad Arlehamn CS, Sette A. T cells from patients with Parkinson’s disease recognize alpha-synuclein peptides. Nature. 2017;546(7660):656–61.
291. Takeda A, Sonoda K-I, Ishishishi T. Regulation of Th1 and Th17 cell differentiation in uveitis. Inflamm Regen. 2013;33(5):261–8.
292. Tamhane UJ, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome: Ann J Cardiol. 2008;102(6):653–7.
293. Taylor AW, Yee DG, Streilein JW. Suppression of nitric oxide generated by immunomodulatory macrophages by calicinogen gene-related peptide in aqueous humor. Invest Ophthalmol Vis Sci. 1998;39(8):1372–8.
294. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87–113.
295. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res. 2008;173:409–21.
296. Tezel G, Edward DP, Wax MB. Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. Arch Ophthalmol. 2009;127(3):301–3.
297. Tezel G, Hernandez R, Wax MB. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch Ophthalmol. 2000;118(4):512–8.
298. Tezel G, Li LY, Patil RV, Wax MB. Th17 cells in human disease. Invest Ophthalmol Vis Sci. 2008;49(12):4230–42.
299. Tezel G, Yang J, Wax MB. Heat shock proteins, immunity and glaucoma. Invest Ophthalmol Vis Sci. 2007;48(2):473–80.
300. Tezel G, Yang X, Luo C, Peng Y, Sun SL, Sun D. Mechanisms of immune system activation in glaucoma: oxidative stress-stimulated antigen presentation by the retina and optic nerve head glia. Invest Ophthalmol Vis Sci. 2007;48(2):705–14.
301. Thomas CN, Berry M, Logan A, Blanch RJ, Ahmed Z. Caspases in retinal ganglion cell death and axon regeneration. Cell Death Discov. 2017;1:17032.
Vendomelle J, Khebizi Q, Fisson S. Cellular and molecular mechanisms of anterior chamber-associated immune deviation (ACAIID): what we have learned from knockout mice. Front Immunol. 2017;8:1686.

Vidal-Sanz M, Salinas-Navarro M, Nadal-Nicolas FM, Alarcon-Martinez L, Valiente-Soriano FJ, de Imperial JM, Aviles-Trigueros M, Agudo-Barrueto M, Villegas-Perez MP. Understanding glaucomatous damage: anatomical and functional data from ocular hypertensive rodent retinas. Prog Retin Eye Res. 2012;31(1):1–27.

Viglietta V, Baecher-Allan C, Weiner HL, Haffer DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199(5):571–8.

Vrabec JP, Levin LA. The neurobiology of cell death in glaucoma. Eye (Lond). 2007;21(Suppl 1):511–14.

Vyas SP, Goswami R. A decade of Th9 cells: role of Th9 cells in inflammatory bowel disease. Front Immunol. 2018;9:1139.

Wajih Ullah M, Qaseem A, Amray A. Post vaccination Guillain Barre syndrome: a case report. Cureus. 2018;10(4):e2511.

Wang GH, Xing YQ. Evaluation of heat shock protein (HSP-72) expression in retinal ganglion cells of rats with glaucoma. Exp Ther Med. 2017;14(2):1577–81.

Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369–95.

Wang P, Luo M, Zhou W, Jin X, Su Z, Yan S, Li Y, Xu C, Cheng R, Huang Y, Lin X, Yao L, Nie H, Jiang Q. Global characterization of peripheral B cells in Parkinson's disease by single-cell RNA and BCR sequencing. Front Immunol. 2022;13:814239.

Wang P, Wang WY, Zhang XD. Increased interleukin-26 expression in proliferative diabetic retinopathy. Int J Ophthalmol. 2019;12(11):1688–92.

Wang S, Wang X, Cheng Q, Ouyang W, Sang X, Liu J, Su Y, Liu Y, Li C, Yang L, Jin L, Wang Z. Autophagy dysfunction, cellular senescence, and abnormal immune-inflammation responses in AMD: from mechanisms to therapeutic potential. Oxid Med Cell Longev. 2019;2019:3632169.

Wax MB. The case for autoimmunity in glaucoma. Exp Eye Res. 2011;93(2):187–90.

Wax MB, Tezel G, Yang J, Peng G, Patil RV, Agarwal N, Sappington RM, Calkins DJ. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci. 2008;28(46):12085–96.

Weinstein JE, Peppe KL. Cytokines in uveitis. Curr Opin Ophthalmol. 2018;29(3):267–74.

Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):S111–9.

Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. F1000Res. 2018;7:1165.

Wheller C, Seksenyan A, Koronyo Y, Rentsoondar A, Sarayba D, Wu H, Gragg A, Siegel E, Thomas D, Espinosa A, Thompson K, Black K, Koronyo-Hamaoui M, Pechnick R, Irvin DK. T-lymphocyte deficiency exacerbates behavioral deficits in the 6-OHDA unilateral lesion rat model for Parkinson's disease. J Neuro Neuropsychophylol. 2014;53.

Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, Smithies O, John SW. Vitamin B3 modulates mitochondrial vulnerability and self tolerance and autoimmunity. Nat Immunol. 2010;11(1):7–13.

Yang L, Guo C, Zhu J, Feng Y, Chen W, Feng Z, Wang D, Sun S, Lin W, Wang Y. Increased levels of pro-inflammatory and anti-inflammatory cellular responses in Parkinson's disease patients: search for a disease indicator. Med Sci Monit. 2017;23:2972–8.

Yang M, Shi XQ, Peyret C, Oladiran Q, Wu S, Chambon J, Fourrier S, Zhang J. Effector/memory CD8+ T cells synergize with co-stimulation competent macrophages to trigger autoimmune peripheral neuropathy. Brain Behav Immun. 2018;71:142–57.

Yang TT, Song SJ, Xue HB, Shi DF, Liu CI, Liu H. Regulatory T cells in the pathogenesis of type 2 diabetes mellitus retinopathy by mir-155. Eur Rev Med Pharmacol Sci. 2015;19(11):2010–5.

Yang X, Luo C, Cai J, Powell DW, Yu D, Kuehn MH, Tezel G. Neurodegenerative and inflammatory pathway components linked to TNF-alpha/ TNFR1 signaling in the glaucomatous human retina. Invest Ophthalmol Vis Sci. 2011;52(1):8442–54.

Yang Z, Quigley HA, Pease ME, Yang Y, Qian J, Valenta D, Zack DJ. Changes in gene expression in experimental glaucoma and optic nerve transection: the balance between protective and detrimental mechanisms. Invest Ophthalmol Vis Sci. 2007;48(12):5539–48.

Yeh S, Li Z, Forooghian F, Hwang FS, Cunningham MA, Pantellini S, Lew JC, Wroblewski KK, Vitale S, Nussenblatt RB. CD4+Foxp3+ T-regulatory cells in noninfectious uveitis. Arch Ophthalmol. 2009;127(4):407–13.

Yokokura Y, Aizawa N, Chiba N, Omokada K, Nakamura M, Otomo T, Yokokura S, Fuse N, Nakazawa T. Significent correlations between optic nerve head microcirculation and visual field defects and nerve fiber layer loss in glaucoma patients with myopic glaucomatous disk. Clin Ophthalmol. 2011;5:1721–7.

Yu HG, Lee DS, Seo JM, Ahn JK, Yu YS, Lee WJ, Chung H. The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behcet’s uveitis. Clin Exp Immunol. 2004;137(2):437–43.

Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurode-structive cytokine produced by glia in the human glaucomatous optic nerve head. Glia. 2000;32(2):42–50.

Yuan N, Zhang HF, Wei Q, Wang P, Guo WY. Expression of CD4+CD25+Foxp3+ regulatory T cells, interleukin 10 and transforming growth factor beta in newly diagnosed type 2 diabetic patients. Exp Clin Endocrinol Diabetes. 2012;126(2):96–101.

Zaidi SAH, Guzman W, Singh S, Mehrotra S, Husain S. Changes in class I and Ilb HDACs by delta-opioid in chronic glaucoma rat model. Invest Ophthalmol Vis Sci. 2020;61(40):474.

Zaidi SAH, Thakore N, Singh S, Guzman W, Singh S, Gargaraju V, Husain S. Histone deacetylases regulation by delta-opioids in human optic nerve head astrocytes. Invest Ophthalmol Vis Sci. 2020;61(1):17.

Zhang J, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27–37.

Zhang N, Bevian MJ. CD8+ T cells: foot soldiers of the immune system. Immunol. 2011;35(2):161–8.

Zhong Q, Fang W, Ma L, Wang ZD, Yang YM, Lu YQ. VEGF levels in plasma correlated with platelet receptor P-selectin expression in Chinese patients with Behcet’s disease. PLoS ONE. 2011;6(4):e18513.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.